Introduction

Improving HIV vaccine trial participation is essential for developing effective prevention strategies in high-burden regions. The PrEPVacc trial, a phase IIb study conducted in East and Southern Africa, represents a significant milestone in this effort. This trial was unique because it combined experimental HIV vaccine regimens with concurrent randomisation to oral pre-exposure prophylaxis (PrEP). Researchers conducted a longitudinal qualitative study to evaluate how participants navigated these complex designs and what factors influenced their decisions to remain in the study.

Enhancing HIV Vaccine Trial Participation Through Clear Communication

A primary finding of the study was that participants achieved a high level of understanding regarding complex concepts. Specifically, they correctly identified the roles of randomisation, double-blinding, and placebo controls. Health workers played a critical role in this process by facilitating repeated information-sharing sessions. Consequently, these frequent interactions built trust and ensured that participants felt informed throughout the 12-month follow-up period. Furthermore, the supportive relationships between clinical staff and participants proved vital for maintaining high retention rates.

Motivations and Barriers in Trial Engagement

Individual perceived risk of HIV infection emerged as a significant motivator for adhering to the oral PrEP component of the trial. While many preferred the potential convenience of a vaccine, they recognised PrEP as a proven protective measure. However, social challenges remained a major hurdle. Misinformation and stigma within local communities often created barriers to participation. Some individuals even reported experiencing social harm or judgment from peers due to their involvement in the study. Therefore, addressing community-level stigma is just as important as ensuring individual clinical safety.

Clinical Implications for Future Research

The success of the PrEPVacc trial in educating its cohort suggests that complex multi-arm designs are feasible when supported by robust communication strategies. For clinicians and researchers in India, where HIV research remains a priority, these insights are invaluable. Strengthening informed consent procedures and engaging family members can significantly improve the acceptability of clinical trials. Additionally, integrating proven prevention methods like PrEP alongside experimental products helps maintain ethical standards and participant interest.

Frequently Asked Questions

What is the PrEPVacc trial design?

PrEPVacc was a phase IIb, three-arm, two-stage trial. It evaluated two different HIV-1 vaccine regimens against a placebo while also randomising participants to different oral PrEP formulations.

Why is repeated communication important in clinical trials?

Frequent sessions with health workers help clarify complex concepts like double-blinding. This ongoing education ensures that HIV vaccine trial participation remains ethical and that participants fully understand their rights and the study's risks.

What were the main barriers to participation?

The main barriers included community stigma and misinformation. These social factors can lead to social harm for participants, making community outreach a necessary component of trial implementation.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Always consult with a qualified healthcare provider for personal health concerns. Refer to the latest local and national guidelines for clinical practice.

References

Kawuma R et al. Understanding trial designs and acceptability of participation in an HIV vaccine trial with concurrent randomisation to oral pre-exposure prophylaxis in East and Southern Africa: a longitudinal qualitative study. Trials. 2026 May 16. doi: 10.1186/s13063-026-09774-5. PMID: 42141483.

PrEPVacc. HIV vaccines tested in PrEPVacc fail to reduce infections. EATG. Published July 23, 2024.

Pharmacy Times. HIV Vaccine Trial Halted Due to Potential Inefficacy, But Oral PrEP Regimens Continue. Published December 14, 2023.